Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 4Phase 1/2 2Phase 2/3 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Head & Neck 2Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasms 4Neoplasm Metastasis 3Melanoma 3Head and Neck Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Esophageal Neoplasms 2Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Solid Tumor 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1NSCLC 1Meningeal Carcinomatosis 1Lymphoma 1Lung Neoplasms 1Kidney Neoplasms 1Hematologic Neoplasms 1Glioma 1Esophageal Squamous Cell Carcinoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × Immune Checkpoint Inhibitors × Clear all
NCT06524570 2026-02-18

iFOCUS

UMC Utrecht

Phase 1 Recruiting
24 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT04417465 2025-09-25

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

AbbVie

Phase 1 Completed
101 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DEKA Biosciences

Phase 1 Active not recruiting
39 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT03790488 2023-07-03

Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies

Jounce Therapeutics, Inc.

Phase 1 Completed
18 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡